Efficacy and Safety of Anti-Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab in Neonates: A Real-World Monocentric Study

Background: RSV remains a leading cause of infant hospitalization worldwide, and the recently approved nirsevimab could represent an effective and safe prophylactic strategy to prevent severe infections in the general neonatal population. Objectives: We conducted a retrospective observational monoce...

Cijeli opis

Bibliografski detalji

Glavni autori:	Maria Costantino, Mariagrazia Bathilde Marongiu, Maria Grazia Corbo, Anna Maria Della Corte, Anna Rita Frascogna, Angela Plantulli, Federica Campana, Luigi Fortino, Emanuela Santoro, Emilia Anna Vozzella, Walter Longanella, Giovanni Boccia, Amelia Filippelli, Francesco De Caro
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-08-01
Serija:	Vaccines
Teme:	Respiratory Syncytial Virus newborns AEFIs nirsevimab
Online pristup:	https://www.mdpi.com/2076-393X/13/8/838
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!